Northern Trust’s Metagenomi Therapeutics MGX Stock Holding History

Northern Trust’s Portfolio MGX Stock Details MGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$101K	Hold	75,172	–	–	﹤0.01%	4107
2025 Q4	$122K	Buy	75,172 +35,198	+88%	+$76.2K	﹤0.01%	4096
2025 Q3	$94.7K	Sell	39,974 -21,858	-35%	-$44.4K	﹤0.01%	4152
2025 Q2	$91.5K	Sell	61,832 -156,718	-72%	-$245K	﹤0.01%	4130
2025 Q1	$297K	Sell	218,550 -5,384	-2%	-$12.8K	﹤0.01%	3794
2024 Q4	$808K	Buy	223,934 +145,536	+186%	+$351K	﹤0.01%	3477
2024 Q3	$170K	Buy	78,398 +64,802	+477%	+$225K	﹤0.01%	3927
2024 Q2	$55.5K	Buy	13,596 +543	+4%	+$3.73K	﹤0.01%	4191
2024 Q1	$138K	Buy	+13,053	New	+$150K	﹤0.01%	3997

Other funds holding MGX

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Trust's MGX Position: Q1 2026 in Review

Northern Trust held its Metagenomi Therapeutics (MGX) position steady in Q1 2026 at 75,172 shares worth $101K. The position accounts for ﹤0.01% of the portfolio, ranked #4107.

Northern Trust first reported a position in MGX in Q1 2024 and has held it in 9 quarters since. The position peaked at $808K in Q4 2024. 48 funds tracked by Wall St. Rank hold MGX as of Q1 2026.

Northern Trust held 75,172 shares of Metagenomi Therapeutics worth $101K as of Q1 2026.
Northern Trust left its Metagenomi Therapeutics share count unchanged in Q1 2026.
Metagenomi Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #4107 holding.
Northern Trust first reported a position in Metagenomi Therapeutics in Q1 2024 and has held it in 9 quarters since.
Northern Trust's Metagenomi Therapeutics position peaked at $808K in Q4 2024.
48 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.